美国生物科技公司莫德纳（Moderna, Inc.，股票代码：MRNA）今日盘前股价大跌5.24%，引发市场广泛关注。这一跌势主要受到公司最新财报、裁员计划以及专利诉讼等多重因素影响。
莫德纳于周五发布了2025年第二季度财报。尽管公司销售额超出华尔街预期，但仍将2025年的销售额预期下调至15亿至22亿美元，比最高预期减少了3亿美元。公司表示，这是由于英国的收入交付将转移到2026年初。此外，莫德纳还宣布将在全球范围内裁员约10%，到今年年底员工人数将缩减至5000人以下，这一消息进一步加剧了投资者的担忧。
与此同时，莫德纳正面临着新冠疫苗销量持续下滑的挑战。公司正努力通过削减成本和开发新产品来应对这一局面。然而，市场似乎对公司的商业策略持怀疑态度，特别是对新冠疫苗和呼吸道合胞病毒（RSV）疫苗的销量反弹缺乏信心。此外，莫德纳在英国的专利诉讼中取得胜利，但这一消息似乎未能提振投资者信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.